Canadian Hospital Using PerkinElmer Tools for Newborn Screening Program

Capital Health of Alberta is using PerkinElmer’s mass spectrometers, reagents, and software in a newborn screening program, PerkinElmer said today.

Under a multi-year agreement, the Edmonton-based Capital Health has bought PerkinElmer’s tandem mass spectrometry systems, reagent kits, and its Specimen Gate software to screen newborns for 17 hereditary metabolic disorders, including cystic fibrosis.  

PerkinElmer said the program will cover the entire province, and makes Alberta the first in Canada to screen all newborns for cystic fibrosis, the company said.  

Financial terms of the agreement were not released.

Source from GenomeWeb Daily News